Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies. ” .

Antibody 111

Antibody Immune Response Protein Vaccination 111

Scienmag

MARCH 1, 2022

The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.

Protein 83

Protein Vaccination Vaccine Antibody 83

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody Development 162

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Clinical data show strong neutralising antibody responses against Omicron BA.1, 1 subvariant of Omicron.

Protein 122

Protein Immune Response Vaccination Vaccine 122

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Scienmag

DECEMBER 27, 2021

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

Antibody 73

Antibody Scientist Protein Vaccination 73

Pharmaceutical Technology

OCTOBER 20, 2022

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Novavax ’s adjuvanted Covid-19 vaccine, NVX-CoV2373, as a booster for use in people aged 18 years and above. The booster is indicated for use after a minimum of six months following a vaccine regimen with an authorised or approved Covid-19 shot.

Vaccination 130

Vaccination Vaccine Antibody Trials 130

Scienmag

DECEMBER 7, 2021

Antibodies against the SARS-CoV-2 spike protein produced by the immune system can help identify and fend off future infections, but not all antibodies are the same. People who either recovered from COVID-19 early in the pandemic or received a current vaccine may not be able to fend off new and emerging variants. […].

Antibody 60

Antibody Vaccination Vaccine Protein 60

Medical Xpress

APRIL 13, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time.

Vaccination 98

Vaccination Vaccine Protein Antibody 98

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 77

Protein Vaccination Vaccine Trials 77

BioSpace

OCTOBER 26, 2021

Nuravax is developing a vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins associated with both AD and Parkinson's disease.

Vaccination 117

Vaccination Vaccine Protein Antibody 117

BioTech 365

JANUARY 14, 2022

Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, … Continue reading (..)

Contract Manufacturing 40

Contract Manufacturing Protein Antibody Manufacturing 40

Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. 1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

BioTech 365

MARCH 29, 2021

Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

Protein 40

Protein Antibody Vaccination Vaccine 40

Pharmaceutical Technology

SEPTEMBER 2, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting expanded conditional marketing authorization (CMA) for Novavax ’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), as a booster in adults aged 18 years and above.

Vaccination 147

Vaccination Vaccine Trials Clinical Trials 147

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. CMV represents a critical unmet medical need, and I believe our two companies have the potential to deliver a truly differentiated vaccine.”.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5 variant spike protein.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Scienmag

MAY 26, 2021

In series of samples collected from individuals vaccinated against COVID-19, an ultrasensitive test detected low concentrations of circulating antigen; Following robust production of antibodies, viral protein declined to undetectable levels The carefully orchestrated dance between the immune system and the viral proteins that induce immunity against (..)

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

BioSpace

JULY 12, 2021

The vaccine candidate ASP3772 generated an antibody response to each of the 24 polysaccharides in its makeup and antibody response to the two conserved pneumococcal proteins.

Vaccination 76

Vaccination Vaccine Antibody Protein 76

BioPharma Reporter

JULY 12, 2021

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiTheraâs COVID-19 vaccine candidate, according to Phase 2 preliminary data.

Vaccination 105

Vaccination Vaccine Protein Antibody 105

Scienmag

JULY 23, 2021

Vaccines against COVID-19, which […].

Antibody 75

Antibody Protein Vaccination Vaccine 75

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 94

Vaccination Vaccine FDA Approval Protein 94

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M,

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Scienmag

FEBRUARY 10, 2022

LA JOLLA, CA—The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research.

Vaccination 76

Vaccination Vaccine Research Protein 76

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Non-injectables remove the need for health professional-led immunisation programmes, making widespread vaccine roll-outs quicker and easier and more affordable,” Channon told pharmaphorum.

Licensing 119

Licensing Licensing Vaccination Vaccine 119

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. This list includes the monoclonal antibody (mAb) PRN100 developed at University College London (UCL) and ALX-002, a treatment developed by Allyx Therapeutics that is also being studied for Alzheimer’s disease.

Drugs 299

Drugs Protein Vaccination Vaccine 299

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52